Precision Medicine Advances in Early Breast Cancer: The Role of Biomarkers in Neo/Adjuvant Therapy

Join us in person at SABCS 2022 or virtually at home for this 1.5-hour live, CME-certified satellite symposium on individualizing therapy for early-stage breast cancer. This interactive event features expert perspectives on the evolving role of biomarkers for perioperative treatment with targeted therapy and immunotherapy. Bring your questions for the question and answer session with the expert faculty.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. SABCS will base its on-site protocols on the latest guidance from the CDC in addition to local regulations in San Antonio. At this time, the City of San Antonio requires masks indoors in all its public facilities, therefore SABCS will require masks for all in-person attendees. SABCS is not legally able to require vaccinations but recommends everyone that is attending the in-person event be vaccinated. Meeting space will be set to accommodate those attendees who prefer more personal space as well as those who prefer to sit closer together.

SABCS will update this plan, as necessary, in accordance with science and any new guidance issued by federal and state authorities.

Additional information about on-site safety protocols will be posted as it becomes available. We encourage you to visit sabcs.org/2022-SABCS to stay abreast of the latest updates.

The content of the presentations and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium®

Agenda

  • Welcome, Overview, Audience Polling Questions
  • Defining Subsets of Patients in EBC in the Era of Precision Medicine
  • Evaluating and Managing High-Risk Disease in HR+/HER2- EBC With and Without gBRCA
  • Panel Discussion I
  • Immune Checkpoint Inhibition and Targeted Therapy in Early TNBC
  • Panel Discussion II
  • Audience Question and Answer Session

Faculty

Program Chair
Joyce O’Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director, 
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Faculty
Melinda Telli, MD

Faculty
Tiffany A. Traina, MD

Associate Professor of Medicine
Weill Medical College 
Vice Chair, Oncology Care
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners caring for patients with early-stage breast cancer.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC 
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO), requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.